Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Masterkey-265 will test the sector’s renewed interest in oncolytic viruses as a way of turning “cold" tumours "hot”.
An adcom for Impulse Dynamics’ heart muscle stimulator is approaching, and the group will want to avoid a nasty shock.
Upcoming readout of the Keynote-522 trial could open up the neoadjuvant triple-negative breast cancer setting for the Merck & Co drug.
Check-Cap has a new spin on capsule endoscopy, using X-rays instead of a visual camera. But more compelling clinical data will be necessary if it is to position its…
Novo Nordisk is determined to dominate obesity, but two discontinuations hint that the ride might be rocky.
The tiny German biotech needs strong signals to emerge from an approaching read out of its chemokine-targeting lead project.